| scholarly article | Q13442814 |
| P50 | author | Hideki Ohdan | Q90330341 |
| Kazuaki Tanabe | Q92289629 | ||
| P2093 | author name string | Nobuaki Fujikuni | |
| Toshihiro Misumi | |||
| P2860 | cites work | Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients | Q24617027 |
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Cutting edge: Expression of functional CD137 receptor by dendritic cells | Q28215568 | ||
| Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells | Q28284490 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity | Q33586493 | ||
| CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells | Q33722711 | ||
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. | Q33827808 | ||
| Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 | ||
| Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity | Q34346238 | ||
| The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer | Q34478504 | ||
| Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma | Q34553839 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies | Q34707604 | ||
| Chemotherapy in gastric cancer: a review and updated meta-analysis | Q35108798 | ||
| Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer | Q35780315 | ||
| Distribution of the FcgammaRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore | Q36025021 | ||
| Immunostimulatory monoclonal antibodies for cancer therapy | Q36717901 | ||
| Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies | Q36787500 | ||
| Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma | Q36975064 | ||
| Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). | Q36999892 | ||
| TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. | Q37028027 | ||
| Properties of mouse and human IgG receptors and their contribution to disease models | Q38005653 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Combinatorial approach to cancer immunotherapy: strength in numbers | Q38852256 | ||
| Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models | Q39519148 | ||
| Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity | Q39908130 | ||
| Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. | Q40457683 | ||
| Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response | Q40621328 | ||
| Fc-Gamma Receptor Polymorphisms Predispose Patients to Infectious Complications After Liver Transplantation. | Q40930837 | ||
| Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. | Q45785465 | ||
| Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. | Q46151045 | ||
| Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. | Q51663342 | ||
| FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer | Q54630456 | ||
| Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules | Q56899602 | ||
| Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 | Q62604205 | ||
| Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 | ||
| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene | Q77535970 | ||
| Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors | Q81310254 | ||
| The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates | Q83092253 | ||
| Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells | Q83288162 | ||
| Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials | Q84402570 | ||
| The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects | Q86727058 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0204880 | |
| P577 | publication date | 2018-10-15 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer | |
| P478 | volume | 13 |
| Q64958587 | The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review. | cites work | P2860 |
Search more.